Objective: Thyroid nodules with nondiagnostic (ND) fine-needle aspirations (FNA) typically undergo repeat sampling. While repeat FNA is often diagnostic, little is known regarding the significance of repeatedly ND aspirates. Limited data suggest there is very low, if any, risk of malignancy for repeatedly ND FNAs. Study Design: We performed a retrospective analysis of ND thyroid FNAs over a nearly 6-year period at our institution to further address this question. Results: There were 834 ND thyroid FNAs, representing 694 distinct thyroid nodules. Repeat FNA was performed after an initial ND aspirate in 52% of cases (363/694); 19% (70/363) had at least one additional ND diagnosis on repeat FNA. Surgical follow-up was available for 57 cases. Malignancy was identified histologically in 21% (9/42) of nodules after a single ND FNA and in 20% (3/15) of nodules with 2 or more repeatedly ND aspirates. Accounting for all benign cytologic follow-up, the overall risk of malignancy was 4% [12/303; 3.5% (9/255) following a single ND FNA and 6.3% (3/48) after repeated ND FNAs]. Conclusion: We observed no modification of malignancy risk when repeated FNAs were ND. Clinical management for an ND aspirate should remain repeat aspiration along with clinical and sonographic correlation.

Keywords:
Thyroid, Bethesda System, Cytology, Fine-needle aspiration, nondiagnostic
1.
Ali SZ, Cibas ES: The Bethesda System for Reporting Thyroid Cytopathology. New York, Springer, 2010.
2.
Baloch ZW, Cibas ES, Clark DP, Layfield LJ, Ljung BM, Pitman MB, Abati A. The National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference: a summation. Cytojournal 2008;5:6.
3.
Cibas ES, Ali SZ: The Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol 2009;132:658–665.
4.
Orija IB, Piñeyro M, Biscotti C, Reddy SS, Hamrahian AH: Value of repeating a nondiagnostic thyroid fine-needle aspiration biopsy. Endocr Pract 2007;13:735–742.
5.
Yang J, Schnadig V, Logrono R, Wasserman PG: Fine-needle aspiration of thyroid nodules: a study of 4,703 patients with histologic and clinical correlations. Cancer 2007;5:306–315.
6.
Nayar R, Ivanovic M: The indeterminate thyroid fine-needle aspiration: experience from an academic center using terminology similar to that proposed in the 2007 National Cancer Institute Thyroid Fine Needle Aspiration State of the Science Conference. Cancer 2009;3:195–202.
7.
Jo VY, Stelow EB, Dustin SM, Hanley KZ: Malignancy risk for fine-needle aspiration of thyroid lesions according to The Bethesda System for Reporting Thyroid Cytopathology. Am J Clin Pathol 2010;134:450–456.
8.
Kim SK, Hwang TS, Yoo YB, Han HS, Kim D, Song K, Lim SD, Kim WS, Paik NS: Surgical results of thyroid nodules according to management guidelines based on BRAF (V600E) mutation status. J Clin Endocrin Metab 2011;96:658–664.
9.
VanderLaan PA, Marqusee E, Krane JF: Clinical outcome for atypia of undetermined significance in thyroid fine-needle aspirations. Am J Clin Pathol 2011;135:770–775.
10.
Renshaw AA: Significance of repeatedly nondiagnostic thyroid fine-needle aspirations. Am J Clin Pathol 2011;135:750–752.
11.
Richards ML, Bohnenblust E, Sirinek K, Bingener J: Nondiagnostic thyroid fine-needle aspiration biopsies are no longer a dilemma. Am J Surg 2008;196:398–402.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.